Pramipexole [
P2879] and its dihydrochloride are non-ergot dopamine agonists with high relative specificity and full intrinsic activity at the D
2 subfamily (D
2, D
3, D
4) of dopamine receptors. The affinity for the D
3 receptor subtype is the highest. Specifically, pramipexoles have selective affinity for the D
2 subfamily (D
2, D
3, D
4), with a 7-10 fold greater affinity for D
3 than for D
2 receptor subtypes; affinity for the D
4 receptor subtype is 17-fold less than for D
3 receptors. In clinical, the dihydrochloride is used for the treatment of Parkinson's disease. Although the precise mechanism of action is unknown, it is believed to be related to its ability to stimulate dopamine receptors in the striatum. (The product is for research purpose only.)